It is the largest European health fund dedicated to start-ups.
Sofinnova has just raised 472 million euros in six months from European, American and Asian institutional investors, against the 350 million initially targeted.
He plans to invest tickets of up to 50 million in biotechs and medical instrumentation companies.
Read also
When old molecules are used to create biotechs
“
In one year, Sofinnova has raised € 1 billion,”
says Antoine Papiernik, president of Sofinnova Partners, the leading European venture capital company dedicated to life sciences
, with
satisfaction.
There is today a real alignment of the planets in Europe around health, once again considered a priority by investors and States.
This is one of the positive effects of Covid.
The urgency is to bring out the future French and European champions in the sector
.
It's time to step on the accelerator.
A momentum illustrated by the decision of Emmanuel Macron to devote 7.5 billion euros to health.
15% yield
It's the
This article is for subscribers only.
You have 69% left to discover.
To cultivate one's freedom is to cultivate one's curiosity.
Continue reading your article for € 1 the first month
I ENJOY IT
Already subscribed?
Log in
